Anti-CD19 CAR-T cell therapy (Sinobioway)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD19 CAR-T cell therapy (Sinobioway)
Drug Alias NameCAR-CD19-modified T cellsCD19-targeted CAR-T cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsImmunologic cytotoxicityT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSinobioway Biomedicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSinobioway Biomedicine Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A